The US Food and Drug Administration (FDA) told makers of popular weight-loss GLP-1 drugs that they must add warning labels about a rare eye condition that can cause sudden blindness.
Manufacturers of Ozempic, Wegovy, Mounjaro and Zepbound must warn about nonarteritic anterior ischemic optic neuropathy (NAION). The disorder happens when vessels supplying blood to the optic nerves become blocked, depriving the nerves of oxygen.